title: Glucagon-like peptides 1 and 2 in health and disease: a review.
abstract: The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as 'incretin' hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent.
authors.affiliation: Discipline of Medicine, University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia. chinmaymarathe@gmail.com
authors.forename: Chinmay S
authors.initials: CS
authors.lastname: Marathe
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Rayner
authors.forename: Karen L
authors.initials: KL
authors.lastname: Jones
authors.forename: Michael
authors.initials: M
authors.lastname: Horowitz
mesh_terms: D000818:Animals; D001786:Blood Glucose; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D005746:Gastric Emptying; D052216:Glucagon-Like Peptide 1 / Q000502:physiology* / Q000627:therapeutic use; D053767:Glucagon-Like Peptide 2 / Q000502:physiology* / Q000627:therapeutic use; D006801:Humans; D054795:Incretins / Q000378:metabolism; D010179:Pancreas / Q000378:metabolism / Q000473:pathology; D019518:Postprandial Period; D018027:Receptors, Glucagon / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D053767:Glucagon-Like Peptide 2; D054795:Incretins; D018027:Receptors, Glucagon; D052216:Glucagon-Like Peptide 1